Search

Your search keyword '"Network Genomic Medicine (NGM)"' showing total 3 results
Start Over Author "Network Genomic Medicine (NGM)"
3 results on '"Network Genomic Medicine (NGM)"'

1. a genomic-based classification of lung tumors

Author

Clinical Lung Cancer Genome Project, Network Genomic Medicine, Biospecimens, data source sites: Alex Soltermann, Holger Moch, Odd Terje Brustugun, Steinar Solberg, Marius Lund Iversen, Åslaug Helland, Thomas Muley, Hans Hoffmann, Philipp A. Schnabel, Yuan Chen, Harry Groen, Wim Timens, Hannie Sietsma, Joachim H. Clement, Walter Weder, Jörg Sänger, Erich Stoelben, Corinna Ludwig, Walburga Engel Riedel, Egbert Smit, Daniëlle A. M. Heideman, Peter J. F. Snijders, Lucia Nogova, Martin L. Sos, Christian Mattonet, Karin Töpelt, Matthias Scheffler, Eray Goekkurt, Rainer Kappes, Stefan Krüger, Kato Kambartel, Dirk Behringer, Wolfgang Schulte, Wolfgang Galetke, Winfried Randerath, Matthias Heldwein, Andreas Schlesinger, Monika Serke, Khosro Hekmat, Konrad F. Frank, Roland Schnell, Marcel Reiser, Ali Nuri Hünerlitürkoglu, Stephan Schmitz, Lisa Meffert, Yon Dschun Ko, Markus Litt Lampe, Ulrich Gerigk, Rainer Fricke, Benjamin Besse, Christian Brambilla, Sylvie Lantuejoul, Philippe Lorimier, Denis Moro Sibilot, Federico Cappuzzo, Claudia Ligorio, John K. Field, Russell Hyde, Pierre Validire, Philippe Girard, Lucia A. Muscarella, Vito M. Fazio, Michael Hallek, Jean Charles Soria, Scott L. Carter, Gad Getz, D. Neil Hayes, Matthew D. Wilkerson, Viktor Achter, Ulrich Lang, DAMIANI, STEFANIA, Clinical Lung Cancer Genome Project (CLCGP), Network Genomic Medicine (NGM), Biospecimens and data source sites: Alex Soltermann, Holger Moch, Odd Terje Brustugun, Steinar Solberg, Marius Lund-Iversen, Åslaug Helland, Thomas Muley, Hans Hoffmann, Philipp A. Schnabel, Yuan Chen, Harry Groen, Wim Timen, Hannie Sietsma, Joachim H. Clement, Walter Weder, Jörg Sänger, Erich Stoelben, Corinna Ludwig, Walburga Engel-Riedel, Egbert Smit, Daniëlle A. M. Heideman, Peter J. F. Snijder, Lucia Nogova, Martin L. So, Christian Mattonet, Karin Töpelt, Matthias Scheffler, Eray Goekkurt, Rainer Kappe, Stefan Krüger, Kato Kambartel, Dirk Behringer, Wolfgang Schulte, Wolfgang Galetke, Winfried Randerath, Matthias Heldwein, Andreas Schlesinger, Monika Serke, Khosro Hekmat, Konrad F. Frank, Roland Schnell, Marcel Reiser, Ali-Nuri Hünerlitürkoglu, Stephan Schmitz, Lisa Meffert, Yon-Dschun Ko, Markus Litt-Lampe, Ulrich Gerigk, Rainer Fricke, Benjamin Besse, Christian Brambilla, Sylvie Lantuejoul, Philippe Lorimier, Denis Moro-Sibilot, Federico Cappuzzo, Claudia Ligorio, Stefania Damiani, John K. Field, Russell Hyde, Pierre Validire, Philippe Girard, Lucia A. Muscarella, Vito M. Fazio, Michael Hallek, Jean-Charles Soria, Scott L. Carter, Gad Getz, D. Neil Haye, Matthew D. Wilkerson, Viktor Achter, and Ulrich Lang

Subjects
genomics, Lung cancer
Abstract

We characterized genome alterations in 1255 clinically annotated lung tumors of all histological subgroups to identify genetically defined and clinically relevant subtypes. More than 55% of all cases had at least one oncogenic genome alteration potentially amenable to specific therapeutic intervention, including several personalized treatment approaches that are already in clinical evaluation. Marked differences in the pattern of genomic alterations existed between and within histological subtypes, thus challenging the original histomorphological diagnosis. Immunohistochemical studies confirmed many of these reassigned subtypes. The reassignment eliminated almost all cases of large cell carcinomas, some of which had therapeutically relevant alterations. Prospective testing of our genomics-based diagnostic algorithm in 5145 lung cancer patients enabled a genome-based diagnosis in 3863 (75%) patients, confirmed the feasibility of rational reassignments of large cell lung cancer, and led to improvement in overall survival in patients with EGFR-mutant or ALK-rearranged cancers. Thus, our findings provide support for broad implementation of genome-based diagnosis of lung cancer.

Published
2013

2. Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[ 18 F]fluoroethyl)-L-tyrosine PET.

Author

Abdulla DSY, Scheffler M, Brandes V, Ruge M, Kunze S, Merkelbach-Bruse S, Nogova L, Michels S, Fischer R, Riedel R, Büttner R, Persigehl T, Grau S, Galldiks N, Drzezga A, Kobe C, and Wolf J

Subjects
Adult, Brain Neoplasms drug therapy, Brain Neoplasms secondary, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung secondary, ErbB Receptors genetics, Female, Humans, Lung Neoplasms drug therapy, Lung Neoplasms pathology, Mutation genetics, Positron-Emission Tomography, Antineoplastic Agents therapeutic use, Brain Neoplasms diagnosis, Carcinoma, Non-Small-Cell Lung diagnosis, Erlotinib Hydrochloride therapeutic use, Lung Neoplasms diagnosis, Tyrosine analogs & derivatives
Published
2019
Full Text
View/download PDF

3. Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center.

Author

Kron F, Kostenko A, Scheffler M, Müller D, Glossmann JP, Fischer R, Michels S, Nogova L, Hallek M, Zander T, and Wolf J

Subjects
Aged, Cancer Care Facilities, Clinical Trials as Topic, Female, Germany epidemiology, Humans, Lung Neoplasms diagnosis, Male, Middle Aged, Neoplasm Staging, Retrospective Studies, Standard of Care, Costs and Cost Analysis, Lung Neoplasms epidemiology
Abstract

Objectives: The recent success of individualized lung cancer therapy has triggered fundamental changes in clinical research strategies. To date there is a strong focus on early proof of concept trials in genetically preselected small patient subgroups. This analysis focuses on the economic burden caused by such trials for advanced lung cancer patients in a German Comprehensive Cancer Center (CCC)., Methods: The profit margins between recruiting groups with ≤3 and >3 patients were compared. Clinical and economic data from clinical trials for advanced lung cancer (LC), pharma-sponsored trials (PhST) as well as investigator initiated trials (IIT), conducted between 2011 and 2015 at the Center for Integrated Oncology (CIO) Cologne, were analyzed using a profit-center calculation model., Results: 161 patients were enrolled in 27 clinical trials. The key economic parameter determining costs and payments was the 'trial visits'. In comparison of the two groups (A≤3; B>3 patients enrolled) we found negative profit margins for the low recruiting group (€ -1444). Concerning the number of visits significant differences were found between PhST and IIT (p=0.009). Additionally, sub-analysis show structural differences in cost composition by conducting PhST and IIT., Conclusion: Trials with low patient numbers and IIT, do not cover the cost. To ensure adequate, cost-covering compensation by pharmaceutical companies CCCs have to thoroughly calculate the cost of early proof of concept trials. The findings of this study also underline the need for novel structures in public funding for investigator-initiated clinical trials in precision medicine., (Copyright © 2017 Elsevier B.V. All rights reserved.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results